1. Phase II study of pemetrexed and carboplatin plus bevacizumab, followed by maintenance pemetrexed and bevacizumab in Japanese patients with non-squamous non-small cell lung cancer
- Author
-
Mina Hayashi, Hiroyuki Sugimoto, Takayasu Kurata, Noriko Inagaki, Shosaku Nomura, Tsutomu Tanijiri, Takayuki Miyara, Yuichi Katashiba, Toshiki Shimizu, Maiko Niki, Kayoko Kibata, Takashi Yokoi, Makoto Ogata, and Yoshitaro Torii
- Subjects
Cancer Research ,medicine.medical_specialty ,Bevacizumab ,medicine.medical_treatment ,Population ,Phases of clinical research ,bevacizumab ,chemotherapy ,Gastroenterology ,chemistry.chemical_compound ,Internal medicine ,Clinical endpoint ,Medicine ,Lung cancer ,education ,pemetrexed ,education.field_of_study ,Chemotherapy ,business.industry ,non-squamous non-small cell lung cancer ,Articles ,medicine.disease ,Carboplatin ,Surgery ,Pemetrexed ,Oncology ,chemistry ,Japanese ,business ,medicine.drug - Abstract
The present study evaluated the efficacy and safety of pemetrexed, carboplatin and bevacizumab, followed by maintenance pemetrexed and bevacizumab, in chemotherapy-naive patients with stage IIIB/IV non-squamous non-small cell lung cancer (NSCLC). The patients were administered pemetrexed (500 mg/m 2 ), carboplatin (area under the concentration-time curve, 6.0 mg/ml x min) and bevacizumab (15 mg/kg) intravenously every three weeks for up to six cycles. Patients who did not experience tumor progression remained on maintenance pemetrexed and beva- cizumab until disease progression or unacceptable toxicity occurred. The primary endpoint was the overall response rate. Of the 26 patients enrolled between March 2010 and April 2011, three were excluded due to brain metastases, therefore the intention-to-treat (ITT) population consisted of 23 patients. The median age was 64 years (range, 40-74 years) and 15 patients were male. In total, six patients had a perfor- mance status of 0, and 20 had stage IV tumors. The response rate was 69.6% (95% confidence interval (CI), 47.1-86.8), the disease control rate was 100% and the time to response was 1.2 months (95% CI, 0.72-1.93). The median progression-free survival time was 8.6 months (95% CI, 5.9-10.9) and the median overall survival time was 18.6 months (95% CI, 12.9- 24.8). There were no grade 3 or worse hemorrhagic events and the feasibility was modest. Overall, pemetrexed and carboplatin plus bevacizumab, followed by maintenance pemetrexed and bevacizumab, was effective and tolerable in the patients with non-squamous NSCLC, and the time to response was relatively short.
- Published
- 2014